\
&
Contact us
\
&
Contact us
This was 2 years ago
Locationonline
ProgrammesCARE4BIO organises the online training “HOW APPLY THE MULTI ACTOR APPROACH IN CLUSTER 6 PROPOSALS”.
The training is free of charge and open to all the potential Cluster 6 applicants interested in exploring the Multi – Actor approach concept and understanding how to include it in the Horizon Europe proposals.
Info and registration: here
The training will explore in depth the definition of the multi-actor approach concept and how it aims to make the R&I process and its outcomes more reliable, demand-driven, shared and relevant to society.
The MAA purpose is to strengthen the process of 'co creation' in the development of a project proposal and to allow practitioners and (end) users to be involved using their practical and local knowledge to develop solutions and create ’co-ownership‘ of results for (end-) users and practitioners. It also aims to have these outcomes shared more extensively.
During the two hours training, officers from European Commission will help us in better understanding the MAA concept, experiences will be shared and analyzed as good practice to understand how to build a good Horizon Multi Actor Approach.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
